Bimatoprost
- Generic Name
- Bimatoprost
- Brand Names
- Durysta, Latisse, Lumigan
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 155206-00-1
- Unique Ingredient Identifier
- QXS94885MZ
- Background
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
- Indication
Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.
Bimatoprost is also indicated to treat eyelash hypotrichosis.
- Associated Conditions
- Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 200
- Registration Number
- NCT02154217
- Locations
- 🇩🇪
Universitaets-augenklinik, Magdeburg, Germany
🇬🇷Department of Ophthalmology, University of Thessaly, University Hos- pital of Larissa, Larissa, Greece
🇮🇹A.O. San Paolo, Milan, Lombardy, Italy
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
- Conditions
- Primary Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02143843
- Locations
- 🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Sall Medical Research Center, Artesia, California, United States
🇺🇸Coastal Research Associates, Atlanta, Georgia, United States
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 100
- Registration Number
- NCT02097719
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 263
- Registration Number
- NCT02061683
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
- Conditions
- Graves' Ophthalmopathy
- Interventions
- Drug: Eye drop solution
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 31
- Registration Number
- NCT02059655
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 87
- Registration Number
- NCT02020512
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 379
- Registration Number
- NCT02017327
- Locations
- 🇫🇷
Laboratoires Théa, Clermont ferrand, France
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG
- Conditions
- Uveitis, AnteriorCystoid Macular Edema
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 69
- Registration Number
- NCT01978015
- Locations
- 🇧🇷
Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil
Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Target Recruit Count
- 67
- Registration Number
- NCT01975714
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionPrimary Open-Angle Glaucoma
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT01915940
- Locations
- 🇺🇸
Ophthalmology Associates PC, Fort Worth, Texas, United States
🇺🇸UNC Kittner Eye Center, Chapel Hill, North Carolina, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.